Shaily Engineering Plastics Ltd — earnings calls
2 quarters summarised from transcripts filed with the exchange, every statement cited. Newest first.
Shaily reported Q1 FY27 consolidated revenue of Rs 281 crore, up 14% year-on-year, with EBITDA of Rs 83 crore and PAT of Rs 48 crore. Healthcare revenue grew 85% to Rs 142 crore and became the largest segment, while Consumer segment revenue declined 24% to Rs 116 crore on softer demand in Europe and the US, and Industrial revenue grew 25% to Rs 23 crore. Management discussed pen injector volumes of about 9 million units in the quarter, capacity expansion plans, new Consumer Electronics and Semiconductor Tray business wins, and progress on healthcare device platforms including emergency-use, reusable and on-body injectors.
Shaily Engineering Plastics reported Q4 FY26 revenue of Rs 237 crore, up 9% year-on-year, with EBITDA of Rs 69 crore and PAT of Rs 40 crore. The Healthcare segment revenue doubled in the quarter and grew 139% for the full year to Rs 393 crore, while the Consumer segment declined 9% for FY26 on weaker demand from Europe and the US. Management also announced commercial launches of Semaglutide pen injectors in Canada and India, a new semiconductor tray supply agreement with a Korean company, and commencement of commercial supplies to a consumer electronics customer.